Quarter Period Consolidated Statement Of Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7608022

Concept 2021-04-01 to
2021-09-30
2021-04-01 to
2021-09-30
2021-04-01 to
2021-09-30
2021-04-01 to
2021-09-30
2021-04-01 to
2021-09-30
Quarter period consolidated statement of income
Statement of income
Net sales
28,504,000,000 JPY
-26,000,000 JPY
2,884,000,000 JPY
28,477,000,000 JPY
25,619,000,000 JPY
Cost of sales
15,051,000,000 JPY
Gross profit (loss)
13,426,000,000 JPY
Selling, general and administrative expenses
Selling, general and administrative expenses
10,768,000,000 JPY
Operating profit (loss)
3,000,000,000 JPY
-342,000,000 JPY
202,000,000 JPY
2,657,000,000 JPY
2,797,000,000 JPY
Non-operating income
Interest income
0 JPY
Dividend income
137,000,000 JPY
Share of profit of entities accounted for using equity method
51,000,000 JPY
Non-operating income
254,000,000 JPY
Non-operating expenses
Interest expenses
29,000,000 JPY
Non-operating expenses
168,000,000 JPY
Ordinary profit (loss)
2,743,000,000 JPY
Extraordinary losses
Impairment losses
5,921,000,000 JPY
Extraordinary losses
6,882,000,000 JPY
Profit (loss) before income taxes
-4,139,000,000 JPY
Income taxes - current
117,000,000 JPY
Income taxes - deferred
-1,460,000,000 JPY
Income taxes
-1,342,000,000 JPY
Profit (loss)
-2,796,000,000 JPY
Profit attributable to
Profit (loss) attributable to owners of parent
-2,796,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
162,000,000 JPY
Remeasurements of defined benefit plans, net of tax
15,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
59,000,000 JPY
Other comprehensive income
237,000,000 JPY
Comprehensive income
-2,559,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
-2,559,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.